Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-25T00:15:58.788Z Has data issue: false hasContentIssue false
  • English
  • Français

Sodium Valproate in Schizophrenia: Some Biochemical Correlates

Published online by Cambridge University Press:  29 January 2018

A. Lautin ,
B. Angrist ,
M. Stanley ,
S. Gershon ,
K. Heckl  and
M. Karobath
A. Lautin
Affiliation:
Department of Psychiatry, New York University Medical Center, 550 First Avenue, New York, NY. 10016
B. Angrist
Affiliation:
Department of Psychiatry, New York University Medical Center, 550 First Avenue, New York, NY. 10016
M. Stanley
Affiliation:
Department of Psychiatry, New York University Medical Center, 550 First Avenue, New York, NY. 10016
S. Gershon
Affiliation:
Department of Psychiatry, New York University Medical Center, 550 First Avenue, New York, NY. 10016
K. Heckl
Affiliation:
Department of Psychiatry, New York University Medical Center, 550 First Avenue, New York, NY. 10016
M. Karobath
Affiliation:
Department of Biochemical Psychiatry, Psychiatrische Universitätsklinik, Lazarettgasse 14, Wien, Austria A1090
Get access Rights & Permissions [Opens in a new window]

Summary

Sodium valproate given in doses of 750–3000 mg daily to eight schizophrenic patients produced a qualitatively similar increase in symptoms in five. CSF showed no significant change in γ-aminobutyric acid or methoxy hydroxyphenyl glycol, but homovanillic acid increased non-significantly in five patients.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 137 , Issue 3 , September 1980 , pp. 240 - 244
Copyright
Copyright © Royal College of Psychiatrists, 1980 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Biggio, G., Casu, M., Corda, M. G., Vernaleone, F. & Gessa, G. L. (1977) Effect of muscimol, a GABA-mimetic agent, on dopamine metabolism in the mouse brain. Life Sciences, 21, 525–32.CrossRefGoogle ScholarPubMed
Davis, K. E., Hollister, L. E. & Berger, P. A. (1976) Baclofen in schizophrenia. Lancet, i, 1245.CrossRefGoogle ScholarPubMed
Dijkhuis, I. C. & Vervloet, E. (1974) Rapid determination of the antiepileptic drug di-n-propylacetic acid in serum. Pharmaceutisch Weekblad, 109, 42–5.Google Scholar
Enna, S. J. & Maggi, A. (1979) Biochemical pharmacology of GABA-ergic agonists. Life Sciences, 24, 1727–38.Google Scholar
Gibson, A. C. (1978) Sodium valproate and tardive dyskinesia. British Journal of Psychiatry, 133, 82.Google Scholar
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology. United States Department of Health, Education and Welfare. Publication No. (ADM) 76–338.Google Scholar
Horton, R. W., Anzelark, G. M., Sawaza, M. C. B. & Meldrum, B. S. (1977) Monoamine and GABA metabolism and the anticonvulsant action of di-n-propylacetate and ethanolamine-o-sulfate. European Journal of Pharmacology, 41, 387–97.Google Scholar
Lautin, A., Stanley, M., Angrist, B. & Gershon, S. (1979) Extrapyramidal syndrome with sodium valproate. British Medical Journal, ii, 1035–6.CrossRefGoogle ScholarPubMed
Linnoila, M., Viukari, M. & Hietala, O. (1976) Effect of sodium valproate on tardive dyskinesia. British Journal of Psychiatry, 129, 114–19.Google Scholar
Nagao, T., Ohshimo, T., Mitsunobu, K., Sato, M. & Otsuki, S. (1979) Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor. Biological Psychiatry, 14, 509–23.Google Scholar
Nutt, J., Williams, A., Plotkin, C., Eng, N., Zeigler, M. & Calne, D. B. (1979) Treatment of Parkinson's disease with sodium valproate: clinical, pharmacological and biochemical observations. Le Journal Canadien des Sciences Neurologiques, 6, 337–43.Google Scholar
Pinder, R. M., Brogden, R. N., Speight, T. M. & Avery, G. S. (1977) Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs, 13, 81–123.CrossRefGoogle ScholarPubMed
Scheel-Krüger, J., Arnt, J., Braestrup, C., Christensen, A. V., Cools, A. R. & Magelund, G. (1978a) GABA–Dopamine interaction in substantia nigra and nucleus accumbens: relevance to behavioral stimulation and stereotyped behavior. In Advances in Biochemical Pharmacology, Vol. 19 (ed. P. J. Roberts et al.) pp 343–346. New York: Raven Press.Google Scholar
Scheel-Krüger, J., Arnt, J., Braestrup, C., Christensen, A. V., & Magelund, G. (1978b) Development of new animal models for GABA-ergic actions using muscimol as a tool. In GABA Neurotransmitters: Pharmachemical, Biochemical and Pharmacological Aspects (eds. P. Krogsgaard-Larsen, J. Scheel-Krüger and H. Kofod) Vol. 12, pp 447–464, The Alfred Benson Symposium Series. Copenhagen: Munksgaard.Google Scholar
Schmid, R. & Karobath, M. (1977) Specific and sensitive method for the determination of γ-aminobutyric acid using gas chromatography with electron capture or mass fragmentographic detection. Journal of Chromatography, 139, 101–9.Google Scholar
Shoulson, I., Kartzinel, R. & Chase, T. N. (1976) Huntington's disease: treatment with dipropylacetic acid and gamma-aminobutyric acid. Neurology, 26, 61–3.Google Scholar
Simpson, G. M., Branchey, M. H. & Shrivastava, R. K. (1976) Baclofen in schizophrenia. Lancet, 966–7.Google Scholar
Spitzer, R. L., Endicott, J. & Robbins, E. (1978) Research Diagnostic Criteria: rationale and reliability. Archives of General Psychiatry, 35, 773–82.CrossRefGoogle ScholarPubMed
Tamminga, C. A., Crayton, J. W. & Chase, T. N. (1978) Muscimol: GABA agonist therapy in schizophrenia. American Journal of Psychiatry, 36, 595–8.Google Scholar
Waser, P. G. (1967) The pharmacology of Amanita muscarina. In Ethnopharmacologic Search for Psychoactive Drugs (eds. D. H. Efron, B. Holmsted and N. S. Kline). U.S. Public Health Service Publication, pp 419–39.Google Scholar
Watson, E. & Wilk, S. (1975) Assessment of cerebrospinal fluid levels of dopamine metabolites by gas chromatography. Psychopharmacologia (Berlin), 42, 57–62.Google Scholar
Wilk, S., Davis, K. L. & Thacker, S. B. (1971) Determination of 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) in cerebrospinal fluid. Annals of Biochemistry, 39, 498–504.Google Scholar
Worms, P. & Lloyd, K. G. (1978) Influence of GABA agonists and antagonists on neuroleptic-induced catalepsy in rats. Life Sciences, 23, 475–8.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.